Simplexia

📍 Stockholm, Sweden👥 5 employees💰 Last funded Jan 2017
Biotechnology Research🌐 simplexia.se
Website LinkedIn
Simplexia is develops vaccine against herpes simplex virus type (HSV-2) infection, which is the most common sexually transmitted infection in the world. The infection causes genital herpes with painful and recurrent genital blisters. HSV-2 can also cause life-threatening encephalitis and meningitis in newborns and immunocompromised patients. A major issue is that HSV-2 infected patients also suffer a three-fold increased risk of HIV acquisition.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investor
All
Early stage
Mid stage
Late stage
Investor geography1 country
Sweden
1
Frequently asked questions
Who invested in Simplexia?
Simplexia has 1 investor on record on gritt.io.
When did Simplexia last raise funding?
The most recent investment in Simplexia recorded on gritt.io was in January 2017.
What industry is Simplexia in?
Simplexia operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Simplexia based?
Simplexia is headquartered in Stockholm, Sweden.